July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomat

MALVERN, Pa.--(BUSINESS WIRE)--Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation and backed by Blackstone Life Sciences, today announced the appointment of Will Kane as President and CEO. Mr. Kane will support the organization’s strategy and growth as it advances solrikitug, its lead asset, toward the completion of three Phase II trials and preparation to move rapidly into Phase III. Mr. Kane joins with more than three decades of biopharmaceutical lea

First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous. Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions. BELLEVUE, Wash. and LA JOLLA, Calif., July 14, 2025 /PRNewswire/ -- Viome Life Sciences, the leader in AI-po

Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation following acute injuries NEW YORK, July 14, 2025 /PRNewswire/ -- Egret Therapeutics today announced the appointment of Dr. Geoffrey Ling, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Ling, a renowned neurologist, Johns Hopkins professor, and former founding director of DARPA's Biological Technologies Office, joins Egret as the company intensifie

Dermatology specialist Leo Pharma has struck a transfer deal with Boehringer Ingelheim, paying 90 million euros ($105 million) up front for rare disease drug Spevigo, which was approved in 2022. For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer Ingelheim 90 million euros ($105 million) up front for the rare disease drug Spevigo.Specializing in dermatology, Denmark-based Leo is well equipped to take contr

GOTHENBURG, Sweden, July 14, 2025 /PRNewswire/ -- Zinzino has initiated a process to acquire 35% of Xion International Group in order to form a joint venture to produce algae using bioreactors. The expanded collaboration is another strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Xion is an innovative, proprietary produ

Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced results from an independent, real-world study evaluating reperfusion outcomes following use of Route 92 Medical’s HiPoint® Reperfusion System, the first and onl

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, the manufacturer of the Edison® Histotripsy System, today announced that Highmark Blue Cross Blue Shield has issued four new positive medical policy decisions for the use of histotripsy in the treatment of liver tumors. The decision expands insurance coverage across Highmark’s commercial plans across four states including New York, Delaware, Pennsylvania, and West Virginia, broadening access to HistoSonics’ non-invasive therapy for approximately 7 milli

SINGAPORE, July 14, 2025 (GLOBE NEWSWIRE) -- Gero, an AI-driven biotechnology company focused on developing therapeutics for age-related diseases, today announced the appointment of Brian Kennedy, Ph.D., to its Board of Directors. Dr. Kennedy is a globally recognized leader in aging biology and translational longevity research. Dr. Kennedy is currently a Distinguished Professor in the Departments of Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of S

First and only medicine approved by Health Canada for patients as young as 6-months of age with HoFH, an ultrarare, inherited form of high cholesterolTORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health Canada has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lo